Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Altocor lovastatin XL: Phase II data; marketed to prevent coronary heart disease

In a placebo-controlled, double-blind Phase II trial in AD patients, 20-80 mg

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE